METHODS FOR DETERMINING CANCER RESPONSIVENESS TO TREATMENTS TARGETING EPITHELIAL CELL GROWTH FACTOR RECEPTOR

• Main Authors: HABER DANIEL A, JOHNSON BRUCE E, PAEZ JUAN GUILLERMO, LYNCH THOMAS J, SELLERS WILLIAM R, SETTLEMAN JEFFREY E, JANNE PASI ANTERO, BELL DAPHNE WINIFRED, SORDELLA RAFFAELLA, MEYERSON MATTHEW
• Format: Patent
• Language: English; Japanese
• Published: 20.04.2017
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide novel methods for determining the likelihood of effectiveness of an epithelial cell growth factor (EGFR) targeting treatment in a human patient affected with cancer, as well as treating methods.SOLUTION: The invention is directed to a method for determining the responsiveness of cancer to an epithelial cell growth factor receptor (EGFR) treatment. In preferred aspects, as the presence of at least one variance in the kinase domain of the erbB 1 gene gives sensitivity to a tyrosine kinase inhibitor gefitinib, a diagnostic assay for these variances enables administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.SELECTED DRAWING: Figure 1 【課題】癌に冒されているヒト患者における上皮細胞成長因子受容体（EGFR）ターゲティング治療の有効性の可能性を決定するための新規方法及び治療法の提供。【解決手段】上皮細胞成長因子受容体（EGFR）治療に対する癌の応答を決定するための方法に向けられる。好ましい態様において、erbB 1遺伝子のキナーゼドメインにおける少なくとも１つの相違の存在は、チロシンキナーゼ阻害剤ゲフィチニブに対する感受性を与える。したがって、これらの突然変異の診断検査法により、最も薬物に応答しそうな患者に対して、ゲフィチニブ、エルロチニブ、およびその他のチロシンキナーゼ阻害剤を投与することができる。【選択図】図１